Enhancing cell and gene therapy manufacture through the application of advanced fluorescent optical sensors (Review).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Harrison RP;Harrison RP; Chauhan VM; Chauhan VM
  • Source:
    Biointerphases [Biointerphases] 2017 Dec 15; Vol. 13 (1), pp. 01A301. Date of Electronic Publication: 2017 Dec 15.
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: AIP Publishing Country of Publication: United States NLM ID: 101275679 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-4106 (Electronic) Linking ISSN: 15594106 NLM ISO Abbreviation: Biointerphases Subsets: MEDLINE
    • Publication Information:
      Publication: 2014 : Melville, NY : AIP Publishing
      Original Publication: [New York, N.Y.] : AVS, c2006-
    • Subject Terms:
      Biotechnology/*methods ; Cell- and Tissue-Based Therapy/*methods ; Genetic Therapy/*methods ; Spectrometry, Fluorescence/*methods ; Technology, Pharmaceutical/*methods; Biotechnology/standards ; Quality Control ; Technology, Pharmaceutical/standards
    • Abstract:
      Cell and gene therapies (CGTs) are examples of future therapeutics that can be used to cure or alleviate the symptoms of disease, by repairing damaged tissue or reprogramming defective genetic information. However, despite the recent advancements in clinical trial outcomes, the path to wide-scale adoption of CGTs remains challenging, such that the emergence of a "blockbuster" therapy has so far proved elusive. Manufacturing solutions for these therapies require the application of scalable and replicable cell manufacturing techniques, which differ markedly from the existing pharmaceutical incumbent. Attempts to adopt this pharmaceutical model for CGT manufacture have largely proved unsuccessful. The most significant challenges facing CGT manufacturing are process analytical testing and quality control. These procedures would greatly benefit from improved sensory technologies that allow direct measurement of critical quality attributes, such as pH, oxygen, lactate and glucose. In turn, this would make manufacturing more robust, replicable and standardized. In this review, the present-day state and prospects of CGT manufacturing are discussed. In particular, the authors highlight the role of fluorescent optical sensors, focusing on their strengths and weaknesses, for CGT manufacture. The review concludes by discussing how the integration of CGT manufacture and fluorescent optical sensors could augment future bioprocessing approaches.
    • Publication Date:
      Date Created: 20171217 Date Completed: 20180713 Latest Revision: 20180713
    • Publication Date:
      20240829
    • Accession Number:
      10.1116/1.5013335
    • Accession Number:
      29246035